NCNicholas Michael Croft

Nicholas Michael Croft

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicholas Michael Croft has a total of 296 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative effectiveness of adalimumab versus infliximab in children with Crohn’s disease: real-world data from the prospective PIBD-SETQuality inception cohort study

    by Stephanie A Vuijk, Renz C W Klomberg, Eva Katgert, Margreet M S Wessels, Erasmo Miele, Fiona L Cameron, Ivan Milovanovich, Rafeeq Muhammed, David Devadason, James Hart, et al.

    Summary: Background: Infliximab and adalimumab are effective anti-tumor necrosis factor (anti-TNF) therapies for the treatment of pediatric Crohn’s disease (CD). The aim of this study was to compare the effectiveness of infliximab and adalimumab in a real-world cohort of children with CD. Methods: Data from biological-naïve children with luminal CD (age 3-18 years) who commenced anti-TNF and completed at least one year of follow-up were collected from the prospective multicenter observational PIBD-SETQuality study. The primary outcome was steroid-free clinical remission (SFCR), defined as clinical remission [wPCDAI <12.5] without systemic steroids or luminal surgery at 1 year. The relative risk (RR) of SFCR was calculated using standardization, correcting for the following baseline covariates: age, upfront anti-TNF, CRP, ESR, albumin, leukocytes, disease behavior, wPCDAI, perianal disease, and concomitant immunomodulator use. Secondary outcomes included the durability of anti-TNF treatment without luminal surgery. Results: Between January 1, 2017, and June 14, 2024, 178 patients with anti-TNF were included (infliximab: n = 121 [68%], adalimumab: n = 57 [32%]). At 12 months, 34/56 (61%) patients treated with adalimumab and 66/120 (55%) patients treated with infliximab had reached SFCR. The RR of SFCR at 1 year with adalimumab compared to infliximab was 1.25 [95% CI 0.94—1.66], p = 0.13. Adalimumab was associated with a significant lower adjusted Hazard Ratio (aHR) of treatment discontinuation than infliximab in patients with a concomitant immunomodulator (aHR 0.17 [95% CI 0.04—0.75], p = 0.020), adjusted for upfront anti-TNF. Conclusions: In this prospective cohort of children with CD, adalimumab and infliximab showed comparable clinical effectiveness one year after the start of anti-TNF treatment.

  • Open Access

    Significant kidney impairment in pediatric inflammatory bowel disease and practice points for pediatric gastroenterologists

    by Stephanie A. Vuijk, Renz C. W. Klomberg, Tobias Schwerd, Anne M. Griffiths, Séamus Hussey, Matthew W. Carroll, Petter Malmborg, Protima Deb, Margreet Wessels, Natalia Mouratidou, et al.

    Objectives: Children with inflammatory bowel disease (IBD) have an increased risk of developing kidney disorders, which may cause significant kidney function impairment (SKI) or lead to chronic kidney disease (CKD). In this study we aimed to provide insights in causes and diagnoses of SKI cases and to provide recommendations for pediatric gastroenterologists for children with IBD and SKI. Methods: Cases of SKI in children with IBD (2 ). Additionally, a panel consisting of 16 members (including experts in pediatric IBD and nephrology) rated the most likely cause of the cases and formulated recommendations for screening, follow‐up and referral for children with IBD and SKI. Results: Between November 1, 2016 and December 31, 2023, 42 cases of SKI were eligible for analysis. Tubulo‐interstitial nephritis (TIN) was the most common diagnosis ( n = 15). Sixteen (38%) cases were confirmed with renal biopsy (10 cases of TIN). Twelve patients developed CKD. IBD medication was the most frequently reported cause ( n = 15), however, there was low concordance between panelists about the most likely etiology (Fleiss' kappa 0.143 and 0.102). Conclusions: This is the first prospective study to report cases of SKI in children with IBD. SKI may lead to CKD. Confirming the etiology of the SKI proved to be very challenging. The study provides recommendations for screening and follow‐up of SKI in children with IBD. Trial Registration: NCT03571373, date of registration: June 27, 2018, URL: https://clinicaltrials.gov/study/NCT03571373

  • Open Access

    Combining mucosal microbiome and host multi-omics data shows prognostic potential in paediatric ulcerative colitis

    by Maria Kulecka, Jill O’sUllivan, Rachel Fitzgerald, Ana Velikonja, Chloe E. Huseyin, Emilio J. Laserna-Mendieta, Patricia Ruiz-Limón, Julia Eckenberger, Miriam Vidal-Marín, Bastian-Alexander Truppel, et al.

    Current first-line treatments of paediatric ulcerative colitis (UC) maintain a 6-month remission in only half of the patients. Relapse prediction at diagnosis could enable earlier introduction of immunosuppressants. We collected intestinal biopsies from 56 treatment-naïve children, combining mucosal quantitative microbial profiling with host epigenomics, transcriptomics, genotyping, and in vitro and in vivo experiments on selected bacteria. Baseline bacterial diversity is lower in relapsing children, who have fewer butyrate producers but more oral-associated bacteria, whereof Veillonella parvula induces inflammation in epithelial cell lines and IL10-/- mice. Microbiota has the strongest association with future relapse, followed by host epigenome and transcriptome. Interferon gamma signalling is also linked to relapse-associated bacteria. Relapse-prediction using separate omics data is outperformed by a robust machine learning approach combining microbiomes and epigenomes. In summary, host-microbe data have prognostic potential in paediatric UC. Our translational findings also suggest that pro-inflammatory oral-associated colonizers can exploit the reduced colonic bacterial diversity of relapsing children.


  • The Risk of Venous Thromboembolism in Children With Inflammatory Bowel Disease

    by Philip R Harvey, David McNulty, Benjamin Coupland, Polychronis Kemos, Nicholas M Croft, Nigel J Trudgill

    Background: Recent studies of children with inflammatory bowel disease (IBD) demonstrate an increased venous thromboembolism (VTE) risk. However, estimates of risk are variable and case numbers are limited. The aim of this study was to provide national estimates of the risk of VTE in children with IBD. Methods: Hospital Episode Statistics was used to identify patients diagnosed with either IBD or VTE before reaching 18 years of age between 2001 and 2019. Populations and subgroups are described, and the risks of developing VTE in the general and IBD populations were calculated. Results: Children with VTE following a diagnosis of IBD or in the previous 6 months (n = 85) and with VTE without IBD (n = 4160) were studied. The absolute risk in children with IBD was 9.42 (95% confidence interval [CI], 7.4-11.4) per 10 000 patient-years, compared with 0.18 (95% CI, 18-0.19) in children without IBD. Between 6 months prior to and 1 year following IBD diagnosis was the highest absolute risk period for VTE (18.0; 95% CI, 13.7-22.4). The relative risk of VTE in children with IBD vs children without IBD was greatest in younger patient groups: the relative risk for the age band 0 to 8 years was 96.5 (95% CI, 51.8-179.9) and for 9 to 11 years was 153.1 (95% CI, 81.2-288.8) vs 14.3 (95% CI, 10.3-20.0) for 15 to 17 years. Cerebral venous sinus thrombosis represented 17.6% of pediatric VTE events in IBD patients compared with 4.2% in children without IBD (P = .001). Conclusions: This study confirms the increased risk of VTE in children with IBD compared with children without IBD. The time of greatest VTE risk was around diagnosis. Cerebral venous sinus thrombosis was significantly more common in children with IBD than other children.


  • Open Access

    The Circulating Methylome in Childhood-Onset Inflammatory Bowel Disease

    by Alexandra Noble, Alex Adams, Jan Nowak, Guo Cheng, Komal Nayak, Aisling Quinn, Mark Kristiansen, Rahul Kalla, Nicholas T Ventham, Federica Giachero, et al.

    The genetic contribution to inflammatory bowel disease (IBD) encompassing both Crohn’s disease (CD) and ulcerative colitis (UC), accounts for around 20% of disease variance, highlighting the need to characterise environmental and epigenetic influences. Recently considerable progress has been made in characterising the adult methylome, in epigenome-wide association studies. We report detailed analysis of the circulating methylome in 86 patients with childhood-onset CD,UC and 30 controls using the Illumina Infinium Human MethylationEPIC platform. We derive and validate a 4-probe methylation biomarker (RPS6KA2, VMP1, CFI and ARHGEF3), with specificity and high diagnostic accuracy for paediatric IBD in UK and North American cohorts (AUC 0.90-0.94). Significant epigenetic age acceleration is present at diagnosis, with the greatest observed in CD patients. Cis-MeQTL analysis identifies genetic determinants underlying epigenetic alterations notably within the HLA 6p22.1-p21.33 region. Passive smoking exposure is associated with the development of UC rather than CD contrary to previous findings. These data provide new insights into epigenetic alterations in IBD and illustrate the reproducibility and translational potential of epigenome-wide association studies in complex diseases.


  • Open Access

    Emerging Patterns of Inflammatory Bowel Disease in Sub-Saharan Africa: 175 Cases From an Inflammatory Bowel Disease Network

    by Phoebe Hodges, Oluwafunmilayo Adeniyi, Smita Devani, Chinenye Nwoko, Opeyemi Owoseni, Kwadwo Gyebi Agyenim Boateng, Anthony Ocanit, Abdallah Muhofa, Nasiru Altine Dankiri, Babatunde Duduyemi, et al.

    There is a knowledge gap on the epidemiology of inflammatory bowel disease in Africa. To begin to address this issue, we formed a case reporting network of practitioners with an interest in inflammatory bowel disease across sub-Saharan Africa. Here, we report a series of 175 cases from 12 countries over 2 years.


  • Open Access

    Improved Clinical Outcomes With Early Anti-Tumour Necrosis Factor Alpha Therapy in Children With Newly Diagnosed Crohn’s Disease: Real-world Data from the International Prospective PIBD-SETQuality Inception Cohort Study

    by Renz C W Klomberg, Hella C van der Wal, Martine A Aardoom, Polychronis Kemos, Dimitris Rizopoulos, Frank M Ruemmele, Mohammed Charrout, Hankje C Escher, Nicholas M Croft, Lissy de Ridder, et al.

    Background and Aims: Treatment guidelines for paediatric Crohn’s disease [CD] suggest early use of anti-tumour necrosis factor alpha [anti-TNFα] in high-risk individuals. The aim is to evaluate the effect of early anti-TNF in a real-world cohort. Methods: Children with newly diagnosed CD were prospectively recruited at 28 participating sites of the international observational PIBD-SETQuality study. Outcomes were compared at 3 months, 1 and 2 years between patients receiving early anti-TNF [<90 days after diagnosis] and those not receiving early anti-TNF. Outcomes included sustained steroid-free remission [SSFR] without treatment intensification [specified as SSFR*] and sustained steroid-free mild/inactive disease without treatment intensification [specified as SSFMI*]. Penalised logistic regression model-based standardisation was applied to estimate the relative risks [RR] of early therapy on outcomes. RRs were estimated for high-risk and low-risk patients, based on presence of predictors of poor outcome [POPOs] and disease activity at diagnosis. Results: In total, 331 children (median age 13.9 years [IQR 12.2–15.3]) were enrolled, with 135 [41%] receiving early anti-TNF. At 1 year, patients on early anti-TNF had higher rates of SSFR* [30% vs 14%, p <0.001] and SSFMI* [69% vs 33%, p <0.001], with RRs of 2.95 [95% CI 1.63-5.36] and 4.67 [95% CI 2.46-8.87], respectively. At 1 year, the RRs for SSFMI* were higher, and statistically significant in high-risk patients, i.e. those with moderate/severe disease compared with mild/inactive disease at diagnosis (5.50 [95% CI 2.51-12.05] vs 2.91 [95% CI 0.92-9.11]), and those with any POPO compared with no POPO (5.05 [95% CI 2.45-10.43] vs 3.41 [95% CI 0.54-21.7]). Conclusion: In this cohort of children with newly-diagnosed CD, early anti-TNF demonstrated superior effectiveness in high-risk patients.


  • Open Access

    Safety and efficacy of multimatrix mesalamine in paediatric patients with mild-to-moderate ulcerative colitis: a phase 3, randomised, double-blind study

    by Nicholas Michael Croft, Bartosz Korczowski, Jarosław Kierkuś, Beatriz Caballero, Manoj Kumar Thakur


  • Open Access

    Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort

    by Ohad Atia, Renz C. W. Klomberg, Lissy de Ridder, Polychronis Kemos, Frank M. Ruemmele, Ben Kang, Sujin Choi, Byung‐Ho Choe, Youra Kang, Dror S. Shouval, et al.

    Summary: Background: Several studies have proposed models to predict disease outcomes in paediatric ulcerative colitis (UC), notably PROTECT, Schechter and PIBD‐ahead, but none has been validated by external cohortsAim: To explore these models in a prospective multicentre inception cohortMethods: Children newly diagnosed with UC in 17 centres were followed at disease onset and 3 and 12 months thereafter, as well as at last visit. Outcomes included steroid‐free remission (SFR) and acute severe colitis (ASC).Results: Of the 223 included children, 74 (34%), 97 (43%) and 52 (23%) presented with mild, moderate and severe disease, respectively. SFR rate was 35% at 3 months and 47% at 12 months (62% of those with mild disease at diagnosis vs. 41% in moderate–severe disease; p = 0.01). Thirty‐six (16%) children developed ASC during the first month after diagnosis, and 53 (24%) during the first year. The AUC of the PROTECT model for predicting SFR at 3 and 12 months was 0.78 [95% CI 0.65–0.92] and 0.57 [95% CI 0.47–0.66], respectively. The sensitivity/specificity/PPV/NPV of Schechter's criteria to predict sustained SFR at 12 months was 50%/60%/35%/74%. ASC was predicted only by the PUCAI score at diagnosis and at 3 months.Conclusions: The PROTECT model had a good predictive utility for SFR at 3 months, but not at 12 months. The other predictive models did not achieve sufficient accuracy, which was far from that reported in the original studies. This highlights the necessity for external validation of any prediction model prior to its implementation into clinical practice.


  • Open Access

    Paediatric Inflammatory Bowel Disease: A Multi-Stakeholder Perspective to Improve Development of Drugs for Children and Adolescents

    by Nicholas M Croft, Lissy de Ridder, Anne M Griffiths, Jeffrey S Hyams, Frank M Ruemmele, Dan Turner, Katharine Cheng, Irja Lutsar, Marco Greco, Zuzanna Gołębiewska, et al.

    Background and Aims: Despite recent approvals for new drugs to treat adults with Crohn’s disease or ulcerative colitis, there are only two approved advanced treatment options [infliximab and adalimumab] for children with inflammatory bowel disease [IBD]. There are many potential new therapies being developed for adult and paediatric IBD. Moreover, regulatory agencies in both the European Union and USA have processes in place to support the early planning and initiation of paediatric studies. Nevertheless, unacceptable delays in approvals for use of drugs in children persist, with an average 7-year gap, or longer, between authorization of new IBD drugs for adults and children.Methods: A 2-day virtual meeting was held during April 14–15, 2021 for multi-stakeholders [clinical academics, patient community, pharmaceutical companies and regulators] to discuss their perspectives on paediatric drug development for IBD.Results: The multi-stakeholder group presented, discussed and proposed actions to achieve expediting the approval of new drugs in development for paediatric IBD.Conclusions: Collaborative action points for all stakeholders are required to make progress and facilitate new drug development for children with IBD.